31,000 Shares in Orthofix Medical Inc. $OFIX Bought by Tejara Capital Ltd

Key Points

• Tejara Capital Ltd made a new investment of $506,000 in Orthofix Medical Inc., acquiring 31,000 shares, totaling approximately 0.08% of the company's stock.
• Orthofix Medical reported a disappointing earnings per share of (-$0.36) for the last quarter, missing analysts' estimates significantly, despite revenue exceeding expectations at $203.12 million.
• Wall Street analysts have given Orthofix Medical a consensus rating of "Moderate Buy" with a price target of $21.50, following recent upgrades and ratings changes by various firms.

Tejara Capital Ltd purchased a new position in shares of Orthofix Medical Inc. (NASDAQ:OFIX - Free Report) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 31,000 shares of the medical device company's stock, valued at approximately $506,000. Tejara Capital Ltd owned approximately 0.08% of Orthofix Medical as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the stock. Russell Investments Group Ltd. increased its position in shares of Orthofix Medical by 4.5% during the first quarter. Russell Investments Group Ltd. now owns 178,213 shares of the medical device company's stock worth $2,907,000 after purchasing an additional 7,640 shares in the last quarter. Nuveen LLC purchased a new stake in Orthofix Medical in the 1st quarter valued at approximately $1,445,000. Connor Clark & Lunn Investment Management Ltd. boosted its holdings in Orthofix Medical by 27.3% in the 1st quarter. Connor Clark & Lunn Investment Management Ltd. now owns 70,622 shares of the medical device company's stock valued at $1,152,000 after purchasing an additional 15,150 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Orthofix Medical by 2.6% in the 1st quarter. Vanguard Group Inc. now owns 2,181,313 shares of the medical device company's stock valued at $35,577,000 after purchasing an additional 54,528 shares in the last quarter. Finally, US Bancorp DE boosted its holdings in Orthofix Medical by 684.6% in the 1st quarter. US Bancorp DE now owns 5,673 shares of the medical device company's stock valued at $93,000 after purchasing an additional 4,950 shares in the last quarter. 89.76% of the stock is currently owned by institutional investors and hedge funds.

Orthofix Medical Trading Down 0.1%

Orthofix Medical stock traded down $0.01 during midday trading on Tuesday, reaching $14.50. The stock had a trading volume of 349,623 shares, compared to its average volume of 326,856. The company has a debt-to-equity ratio of 0.38, a current ratio of 2.67 and a quick ratio of 1.50. The firm has a market cap of $572.61 million, a price-to-earnings ratio of -4.57 and a beta of 0.82. The firm's fifty day simple moving average is $11.48 and its two-hundred day simple moving average is $13.68. Orthofix Medical Inc. has a twelve month low of $10.24 and a twelve month high of $20.73.

Orthofix Medical (NASDAQ:OFIX - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The medical device company reported ($0.36) earnings per share for the quarter, missing analysts' consensus estimates of $0.04 by ($0.40). Orthofix Medical had a negative return on equity of 25.43% and a negative net margin of 15.29%.The company had revenue of $203.12 million during the quarter, compared to analyst estimates of $196.89 million. Orthofix Medical has set its FY 2025 guidance at EPS. Equities analysts anticipate that Orthofix Medical Inc. will post -2.81 EPS for the current fiscal year.

Insider Transactions at Orthofix Medical

In other news, insider Aviva Mcpherron sold 3,728 shares of the business's stock in a transaction dated Wednesday, June 18th. The shares were sold at an average price of $10.51, for a total transaction of $39,181.28. Following the transaction, the insider directly owned 46,322 shares in the company, valued at $486,844.22. The trade was a 7.45% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 1.30% of the company's stock.

Analyst Ratings Changes

Several research analysts recently issued reports on the company. JMP Securities restated a "market perform" rating on shares of Orthofix Medical in a research report on Friday, June 6th. Barrington Research raised shares of Orthofix Medical to a "strong-buy" rating and set a $16.00 price target for the company in a research report on Monday, June 23rd. Finally, Wall Street Zen raised shares of Orthofix Medical from a "sell" rating to a "hold" rating in a research report on Saturday, August 9th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Hold rating to the company's stock. According to MarketBeat, the company has an average rating of "Buy" and an average target price of $21.50.

Orthofix Medical Company Profile

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.